Identifying a blood biomarker for brain injury after spontaneous bleeding in the brain
Official title: Advancing a Prognostic and Monitoring Biomarker of Neutrophil-driven Secondary Brain Injury in Spontaneous Intracerebral Hemorrhage for Neurotherapeutics Development
Funded at Boston University Medical Campus · NIH-11042395 · Data updated 2026-11-12
This study is looking at a specific blood marker that could help doctors predict and track brain injury in people who have had a serious type of stroke called spontaneous intracerebral hemorrhage, so they can better understand how to treat and monitor their recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $704,313 |
| NIH project number | 1R61NS135285-01A1 |
| Project ID | NIH-11042395 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who have experienced spontaneous intracerebral hemorrhage without anticoagulant therapy or immunological deficiencies.
✕Less likely to help
Patients with other types of strokes or those receiving anticoagulant therapy may not benefit from this research.
What this research studies
This research focuses on spontaneous intracerebral hemorrhage (sICH), a severe type of stroke that leads to high rates of death and disability. The goal is to identify a specific blood biomarker related to neutrophil activity that can predict and monitor secondary brain injury in patients. By analyzing a unique subset of neutrophils, the study aims to develop a standardized method for measuring this biomarker, which could help in better patient stratification for clinical trials and monitoring disease progression. The research will involve a diverse group of patients who have experienced this type of brain injury.
Why it matters
Potential benefit: If successful, this research could lead to improved prognostic tools and monitoring strategies for patients suffering from spontaneous intracerebral hemorrhage.
How similar studies have gone: While this approach is innovative, it builds on previous research that has explored biomarkers in brain injury, indicating potential for success.
Where this research is happening
-
Boston University Medical Campus
Boston, United States Active
Researchers
- Principal investigator: Herrera, Victoria L — Boston University Medical Campus
- Study coordinator: Herrera, Victoria L
Related research
Other NIH-funded projects on the same topics.
-
Blood marker to predict and track worsening brain injury after a spontaneous brain bleed
This project looks at a blood marker called DEspR+CD11b+ neutrophils to help predict or track worsening brain injury in people after a spontaneous intracerebral hemorrhage.
-
Anticoagulation in ICH Survivors with Atrial Fibrillation and Small Vessel Disease
This project looks at how to safely use blood-thinning medicines in people who survived a brain bleed and also have atrial fibrillation and small vessel disease.
-
Statin use after lobar intracerebral hemorrhage
This trial compares continuing versus stopping statins in people who had a lobar intracerebral hemorrhage to see how that affects repeat brain bleeds, strokes, heart attacks, and recovery over two years.
-
Statin use after lobar brain hemorrhage
This trial compares stopping versus continuing statin medicine in people who had a lobar brain bleed to learn effects on repeat bleeding and future heart or stroke events.
-
Blocking red blood cell death after brain hemorrhage
A study at Yale is exploring whether stopping a specific kind of red blood cell death after a brain hemorrhage could improve recovery.
-
Targeting HDAC3 to reduce brain damage after a brain bleed
This project will test whether blocking a protein called HDAC3 can reduce inflammation and improve recovery after an intracerebral hemorrhage (brain bleed).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.